Depth of response and time to event analysis in patients undergoing combined BRAF/MEK inhibition. (A) Paraprotein reductions after start of treatment for all patients enrolled in the trial. Percentage of paraprotein reduction compared with the baseline value is provided. The individual measurable paraprotein test, according to IMWG response criteria and guidelines, is provided for each patient. Patients are ordered from left to right based on best overall response achieved. The color code indicates the IMWG response category for each patient. FLC, free-light-chain test; IgA, nephelometric detection of quantitative immunoglobulin A; MPROT, M protein detected by serum protein electrophoresis; UPROT, M protein detected by urine protein electrophoresis from 24-hour urine. (B) Swimmer plot displays time to events for enrolled patients by patient number (y-axis) and time since first study drug administration (x-axis). The color code provides information on the best overall response achieved for each patient as per IMWG criteria. The lengths of the horizontal bars indicate the durations of treatment with encorafenib and binimetinib. Additional information provided in the plot per patient: the time points of death events, first response, and progression. The arrow added to the horizontal bar of patient 9 indicates that this patient continued therapy after the database lock and had an uninterrupted partial response. The treatment discontinuation in patient 8 was due to an allogeneic transplantation as indicated. Refer to the main text for details on patient 12 with continued therapy despite formal progressive disease, resulting in a second response, as indicated. alloSCT, allogenic stem cell transplantation; EOT, end of treatment; MR, minimal response; PD, progressive disease.